Ono Pharmaceutical Co., Ltd.
Clinical trials sponsored by Ono Pharmaceutical Co., Ltd., explained in plain language.
Japanese pharmaceutical company focused on oncology and immunology.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
New drug ONO-7428 enters first human tests for advanced cancers
Disease control OngoingThis early-phase study tests a new drug called ONO-7428 in about 60 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to see if the drug is safe and tolerable, and to find the right dose. Participants will receive the drug and be m…
Phase: PHASE1 • Sponsor: Ono Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
New pill could tame blistering skin disease without high steroid doses
Disease control OngoingThis phase 3 study tests an experimental drug called tirabrutinib for people with pemphigus, a rare autoimmune disease that causes painful blisters on skin and mucous membranes. The trial enrolls 34 adults whose disease is not well controlled by steroids. Participants receive eit…
Phase: PHASE3 • Sponsor: Ono Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
New hope for rare brain disorder: drug trial targets MSA
Disease control OngoingThis study tests an experimental drug called ONO-2808 in people with multiple system atrophy (MSA), a rare and serious brain disease. About 92 participants will receive either the drug or a placebo daily for up to 80 weeks. The goal is to see if the drug is safe and might help co…
Phase: PHASE2 • Sponsor: Ono Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Triple therapy aims to outsmart stomach cancer
Disease control OngoingThis Phase 3 trial tests whether adding two immunotherapy drugs (nivolumab and ipilimumab) to standard chemotherapy helps people with advanced HER2-negative stomach or gastroesophageal junction cancer live longer. About 626 participants who have not had prior chemotherapy will re…
Phase: PHASE3 • Sponsor: Ono Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New pill shows promise against rare brain cancer
Disease control OngoingThis phase 2 trial tests tirabrutinib, a targeted cancer pill, in 119 people with primary central nervous system lymphoma (PCNSL), a rare brain cancer. Part A looks at patients whose cancer has returned or not responded to prior treatment. Part B tests tirabrutinib combined with …
Phase: PHASE2 • Sponsor: Ono Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
New hope for stomach cancer: experimental drug combo tested
Disease control OngoingThis phase 2 trial tests whether adding an experimental drug (ONO-4578) to standard immunotherapy (nivolumab) and chemotherapy helps people with advanced HER2-negative stomach cancer. About 226 participants who have not had prior chemotherapy will receive either the experimental …
Phase: PHASE2 • Sponsor: Ono Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New Alzheimer's drug shows promise in Mid-Stage trial
Disease control OngoingThis study tests a new medicine called ONO-2020 in 240 people with mild to moderate Alzheimer's disease. The goal is to see if it can safely improve memory and thinking skills. Participants will receive either the drug or a placebo for 26 weeks, and researchers will track side ef…
Phase: PHASE2 • Sponsor: Ono Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC